» Articles » PMID: 5004004

Effective Protection of Monkeys Against Death from Street Virus by Post-exposure Administration of Tissue-culture Rabies Vaccine

Overview
Specialty Public Health
Date 1971 Jan 1
PMID 5004004
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Three series of experiments on rabies vaccines were carried out on rhesus monkeys using suckling-mouse-brain vaccine, rabbit-brain vaccine, duck-embryo vaccine, and purified, concentrated tissue-culture vaccine. The latter was prepared in a human diploid cell strain and inactivated with beta-propiolactone, and consisted of tissue-culture fluid concentrated 200-fold with a final infectivity titre of 10(9.8) plaque-forming units per ml before inactivation. In the first two series of experiments, several vaccines were tested for relative immunogenicity on a pre-exposure basis. In the third series, a successful model was developed in which a single inoculation of the tissue-culture vaccine administered after exposure to rabies virus, with or without accompanying standard doses of antirabies serum, was evaluated as a method of prevention. A single dose of the tissue-culture vaccine protected 7 out of 8 monkeys from death by street virus. Homologous or heterologous antirabies serum alone gave poor results. The results indicate great promise for prophylaxis in man with one dose, or perhaps a few doses, of highly concentrated, purified tissue-culture vaccine.

Citing Articles

Post-exposure prophylactic vaccine candidates for the treatment of human Risk Group 4 pathogen infections.

Logue J, Crozier I, Jahrling P, Kuhn J Expert Rev Vaccines. 2020; 19(1):85-103.

PMID: 31937163 PMC: 7011290. DOI: 10.1080/14760584.2020.1713756.


Four Thousand Years of Concepts Relating to Rabies in Animals and Humans, Its Prevention and Its Cure.

Tarantola A Trop Med Infect Dis. 2018; 2(2).

PMID: 30270864 PMC: 6082082. DOI: 10.3390/tropicalmed2020005.


Subversion of the Immune Response by Rabies Virus.

Scott T, Nel L Viruses. 2016; 8(8).

PMID: 27548204 PMC: 4997593. DOI: 10.3390/v8080231.


Generation and Characterization of an scFv Directed against Site II of Rabies Glycoprotein.

Aavula S, Nimmagadda S, Biradhar N, Sula S, Chandran D, Lingala R Biotechnol Res Int. 2011; 2011:652147.

PMID: 22007309 PMC: 3189463. DOI: 10.4061/2011/652147.


Rabies vaccine. Developments employing molecular biology methods.

Paolazzi C, Perez O, De Filippo J Mol Biotechnol. 1999; 11(2):137-47.

PMID: 10464768 DOI: 10.1007/BF02915807.


References
1.
SIKES R, Larghi O . Purified rabies vaccine: development and comparison of potency and safety with two human rabies vaccines. J Immunol. 1967; 99(3):545-53. View

2.
WIKTOR T, Kuwert E, KOPROWSKI H . Immune lysis of rabies virus-infected cells. J Immunol. 1968; 101(6):1271-82. View

3.
Sokol F, Kuwert E, WIKTOR T, Hummeler K, KOPROWSKI H . Purification of rabies virus grown in tissue culture. J Virol. 1968; 2(8):836-49. PMC: 375698. DOI: 10.1128/JVI.2.8.836-849.1968. View

4.
Hummeler K, KOPROWSKI H . Investigating the rabies virus. Nature. 1969; 221(5179):418-21. DOI: 10.1038/221418a0. View

5.
WIKTOR T, Sokol F, Kuwert E, KOPROWSKI H . Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin. Proc Soc Exp Biol Med. 1969; 131(3):799-805. DOI: 10.3181/00379727-131-33981. View